• Preclinical studies have demonstrated the potential of PXL770 for Phase II development in the treatment of ADPKD
• Efficacy data from preclinical studies confirm the interest of the strategic orientation of PXL770 in rare metabolic diseases
LYON, France, October 3, 2022 – POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic diseases , today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to PXL770 for the treatment of patients with autosomal dominant polycystic kidney disease (ADPKD). PXL770 is a novel direct activator of adenosine monophosphate-activated protein kinase (AMPK), ready to enter Phase II development for the treatment of ADPKD, subject to additional funding.
To receive information from POXEL in real time, send a request to [email protected].